WO9707750



The present invention relates to the management of pain without requiring or allowing for reduction in the level of administration of narcotics, and to self-management of pain on an outpatient basis. Accordingly, the present invention is broadly directed to a method for treating pain in a subject comprising administering via a transmucosal, transdermal, or oral route a dose of ketamine effective to alleviate pain to a subject suffering from pain. The invention is further directed to a method for synergistically treating pain in a subject comprising administering via any route a dose of ketamine effective to allow for reduction in the level of an ongoing pain therapy, or decrease pain (improve the level of pain relief), or both. Transmucosal, transdermal, and oral administration of ketamine advantageously allows for patient self administration of the drug, which provides for pain management on an outpatient basis. Moreover, ketamine administration in transdermal devices (suppositories, candies, buccal patches) is generally socially acceptable. In a specific example, a patient suffering from intractable bladder pain controlled breakthrough pain by transmucosal (nasal) administration of about 16 mg to about 32 mg of ketamine per dose.






DE19543003



The method uses a rapidly evaporating liquid sprayed on to the area for therapy with high velocity. The liquid is sucked through a guide pipe (6) to an exit nozzle (5), whence it is sprayed. The surrounding air is guided through an air accelerator (2) via a hose (4) to the same nozzle. The flow speed of the air as well as the quantity and droplet size of the sprayed liquid are regulated according to the extraction of heat from the skin. The skin temperature is measured by an infra-red ntidepressant. The liquid to be sprayed is a mixture of medicaments and/or aromatic material. Instead of this liquid, alcohol and/or ether can be used.






RU2108789



FIELD: medicine, veterinary science. SUBSTANCE: invention proposes a method of organism protection from extreme and stress effects by intramuscular or intragastral administration of composition an aqueous solutions at subtoxic doses (1-300 mg/kg). Composition has highly dispersed metallic silver and poly-N-vinylpyrrolidone of molecular mass (6-40) x $$$ Da at the following ratio of components, mas. p. p.: poly-N-vinylpyrrolidone 1, and silver 0.01-2.33. Method can be used for therapy of acute hypoxic states, brain and heart ischemia, shock, stress and as an analgetic for pain relief and an antidepressant. Method can be used also for physiological stimulation of organism adaptation to nonfavorable extreme factors using low-toxic biologically active substances. EFFECT: high effectiveness, absence of by-side effects.






GB2255719



Electro-therapy apparatus delivers modulated or mixed electromagnetic signal to a patient via electrodes A, B of substantially different sizes, so that the small electrode B provides a targeted and specific therapeutic effect. Typically the effect may be of pain relief. Two high frequency signals f1 and f2 may be mixed to deliver a signal having a beat frequency (f2 - f1) of 1 to 250 Hz, and the area of the electrode B at the treatment site may be over 50 times smaller than the other electrode A. The signal may be switched between a plurality of electrodes (B1 to B4).